{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:20:44Z","timestamp":1776424844772,"version":"3.51.2"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,14]],"date-time":"2027-01-14T00:00:00Z","timestamp":1799884800000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.trim.2026.102345","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:09:54Z","timestamp":1767974994000},"page":"102345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Impact of everolimus-based immunosuppression on transplant rejection or death in lung transplant recipients using the United States Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1016","volume":"94","author":[{"given":"Toru","family":"Ogura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Urawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.trim.2026.102345_bb0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5500\/wjt.v10.i5.104","article-title":"Chronic lung allograft dysfunction post-lung transplantation: the era of bronchiolitis obliterans syndrome and restrictive allograft syndrome","volume":"10","author":"Yoshiyasu","year":"2020","journal-title":"World J. Transplant."},{"issue":"1","key":"10.1016\/j.trim.2026.102345_bb0010","first-page":"5","article-title":"Individualizing immunosuppression in lung transplantation","volume":"2018","author":"McDermott","year":"2018","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"10.1016\/j.trim.2026.102345_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.10704","article-title":"Everolimus based immunosuppression strategies in adult lung transplant recipients: calcineurin inhibitor minimization versus calcineurin inhibitor elimination","volume":"36","author":"Ivulich","year":"2023","journal-title":"Transpl. Int."},{"issue":"10","key":"10.1016\/j.trim.2026.102345_bb0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1042\/CS20150149","article-title":"Cellular and molecular effects of the mTOR inhibitor everolimus","volume":"129","author":"Saran","year":"2015","journal-title":"Clin. Sci."},{"issue":"6","key":"10.1016\/j.trim.2026.102345_bb0025","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/ajt.15251","article-title":"A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation","volume":"19","author":"Gottlieb","year":"2019","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.trim.2026.102345_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trre.2012.11.001","article-title":"Recommendations on the use of everolimus in lung transplantation","volume":"27","author":"De Pablo","year":"2013","journal-title":"Transplant. Rev."},{"issue":"1","key":"10.1016\/j.trim.2026.102345_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13665-025-00378-z","article-title":"Immunosuppression in lung transplantation: current and emerging therapies","volume":"14","author":"Barnes","year":"2025","journal-title":"Curr. Pulmonol. Rep."},{"issue":"2","key":"10.1016\/j.trim.2026.102345_bb0040","article-title":"Approach to detecting beneficial and detrimental drug-drug interactions in complex pharmacotherapy","volume":"17","author":"Ogura","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.trim.2026.102345_bb0045","author":"Food and Drug Administration"},{"key":"10.1016\/j.trim.2026.102345_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2023.101900","article-title":"Analysis of death avoidance by concomitant use of prednisone in patients with renal transplant using the Food and Drug Administration Adverse Event Reporting System","volume":"80","author":"Ogura","year":"2023","journal-title":"Transpl. Immunol."},{"issue":"5","key":"10.1016\/j.trim.2026.102345_bb0055","article-title":"Efficacy of prednisone avoidance in patients with liver transplant using the US Food and Drug Administration Adverse Event Reporting System","volume":"16","author":"Ogura","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.trim.2026.102345_bb0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4285\/ctr.24.0049","article-title":"Comparing drug combinations for graft-versus-host disease prophylaxis using the U.S. Food and Drug Administration Adverse Event Reporting System","volume":"39","author":"Ogura","year":"2025","journal-title":"Clin. Transplant. Res."},{"issue":"7","key":"10.1016\/j.trim.2026.102345_bb0065","article-title":"Comparison of adverse events following immunosuppressant administration for pediatric patients with renal transplants categorized by two-year age increments using the US Food and Drug Administration Adverse Event Reporting System","volume":"16","author":"Ogura","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.trim.2026.102345_bb0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40261-022-01242-7","article-title":"Comparison of adverse events occurred during administration of dipeptidyl peptidase-4 inhibitor in patients with diabetes using FDA Adverse Event Reporting System","volume":"43","author":"Ogura","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.trim.2026.102345_bb0075","series-title":"Statistical Analysis with Missing Data","author":"Little","year":"2019"},{"key":"10.1016\/j.trim.2026.102345_bb0080","series-title":"A Language and Environment for Statistical Computing","author":"R Core Team, R","year":"2025"},{"issue":"1","key":"10.1016\/j.trim.2026.102345_bb0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/TP.0000000000004336","article-title":"Mammalian target of rapamycin inhibitors and kidney function after thoracic transplantation: a systematic review and recommendations for management of lung transplant recipients","volume":"107","author":"Schmucki","year":"2023","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.trim.2026.102345_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.critrevonc.2013.06.001","article-title":"Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis","volume":"88","author":"Funakoshi","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.trim.2026.102345_bb0095","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12672-024-01329-x","article-title":"The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex","volume":"15","author":"Qiu","year":"2024","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.trim.2026.102345_bb0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4285\/kjt.23.0003","article-title":"A systematic review and meta-analysis comparing everolimus and calcineurin inhibitors (CNIs) to mycophenolate and CNIs in kidney transplant patients","volume":"37","author":"Vergara-Rejante","year":"2023","journal-title":"Korean J. Transplant."},{"issue":"2","key":"10.1016\/j.trim.2026.102345_bb0105","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.transproceed.2006.10.092","article-title":"Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus","volume":"38","author":"Kovarik","year":"2006","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2026.102345_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IJNRD.S4191","article-title":"The use of everolimus in renal-transplant patients","volume":"2","author":"Pascual","year":"2009","journal-title":"Int. J. Nephrol. Renov. Dis."},{"issue":"1","key":"10.1016\/j.trim.2026.102345_bb0115","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1186\/1471-2407-14-906","article-title":"Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function","volume":"14","author":"Ha","year":"2014","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.trim.2026.102345_bb0120","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.21037\/jtd-23-1623","article-title":"mTOR inhibitors after lung transplantation: a real-life experience","volume":"16","author":"Schmucki","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.trim.2026.102345_bb0125","article-title":"Everolimus and malignancy after solid organ transplantation: a clinical update","volume":"2016","author":"Holdaas","year":"2016","journal-title":"J. Transp."},{"issue":"17","key":"10.1016\/j.trim.2026.102345_bb0130","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.trim.2026.102345_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.intimp.2015.11.020","article-title":"Effects of mTOR and calcineurin inhibitors combined therapy in Epstein\u2013Barr virus positive and negative Burkitt lymphoma cells","volume":"30","author":"Wowro","year":"2016","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.trim.2026.102345_bb0140","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.healun.2021.06.004","article-title":"Gender and racial disparities in lung transplantation in the United States","volume":"40","author":"Riley","year":"2021","journal-title":"J. Heart Lung Transplant."},{"issue":"2","key":"10.1016\/j.trim.2026.102345_bb0145","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/j.ajt.2024.01.017","article-title":"OPTN\/SRTR 2022 annual data report: lung","volume":"24","author":"Valapour","year":"2024","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.trim.2026.102345_bb0150","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/j.ajt.2023.02.009","article-title":"OPTN\/SRTR 2021 annual data report: lung","volume":"23","author":"Valapour","year":"2023","journal-title":"Am. J. Transplant."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632742600002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632742600002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:31:44Z","timestamp":1769257904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096632742600002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"alternative-id":["S096632742600002X"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2026.102345","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of everolimus-based immunosuppression on transplant rejection or death in lung transplant recipients using the United States Food and Drug Administration Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2026.102345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102345"}}